Hormone replacement therapy and mid-term implant survival following knee or hip arthroplasty for osteoarthritis: A population-based cohort study

Annals of the Rheumatic Diseases

Volumn 74, Issue 3, 2015, Pages 557-563

  Prieto Alhambra, D ^a,b,c,d,e   Javaid, M K ^a   Judge, A ^a,b   Maskell, J ^b   Cooper, C ^a,b   Arden, N K ^a   Mullee, Mark ^a   Rafferty, James ^a   Carr, Andrew ^a   Price, Andrew ^a   Javaid, Kassim ^a   Beard, David ^a   Altman, Douglas ^a   Clarke, Nicholas ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GRAFT SURVIVAL; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MEDICATION COMPLIANCE; OSTEOARTHRITIS; OSTEOLYSIS; OUTCOME ASSESSMENT; POPULATION RESEARCH; PROSTHESIS LOOSENING; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; WOMEN'S HEALTH; AGED; ESTROGEN THERAPY; HIP ARTHROPLASTY; KNEE ARTHROPLASTY; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PROPORTIONAL HAZARDS MODEL; PROSTHESIS FAILURE; REOPERATION; RETROSPECTIVE STUDY; UTILIZATION;

AGED; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; COHORT STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PROPORTIONAL HAZARDS MODELS; PROSTHESIS FAILURE; REOPERATION; RETROSPECTIVE STUDIES;

EID: 84922374355     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204043     Document Type: Article

References (36)

1. National Joint Registry. National Joint Registry for England and Wales. 8th Annual Report; 2011.
2. Harris WH, Sledge CB. Total Hip and Total Knee Replacement. N Engl J Med 1990;323:725-31.
3. Carr AJ, Robertsson O, Graves S, et al. Knee replacement. Lancet 2012;379:1331-40.
4. Culliford DJ, Maskell J, Beard DJ, et al. Temporal trends in hip and knee replacement in the United Kingdom: 1991 TO 2006. J Bone Joint Surg Br 2010;92-B:130-5.
5. Otten R, van Roermund PM, Picavet HS. [Trends in the number of knee and hip arthroplasties: considerably more knee and hip prostheses due to osteoarthritis in 2030]. Ned Tijdschr Geneeskd 2010;154:A1534.
6. Bozic KJ, Kurtz SM, Lau E, et al. The Epidemiology of Revision Total Hip Arthroplasty in the United States. J Bone Joint Surg Am 2009;91:128-33.
7. Hossain F, Patel S, Haddad F. Midterm Assessment of Causes and Results of Revision Total Knee Arthroplasty. Clin Orthop Relat Res 2010;468:1221-8.
8. Sibanda N, Copley LP, Lewsey JD, et al. Revision Rates after Primary Hip and Knee Replacement in England between 2003 and 2006. PLoS Med 2008;5:e179.
9. Goodship AE, Blunn GW, Green J, et al. Prevention of strain-related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate. J Orthop Res 2008;26:693-703.
10. Hilding M, Aspenberg P. Postoperative clodronate decreases prosthetic migration: 4-year follow-up of a randomized radiostereometric study of 50 total knee patients. Acta Orthopaedica 2006;77:912-16.
11. Hilding M, Aspenberg P. Local peroperative treatment with a bisphosphonate improves the fixation of total knee prostheses: A randomized, double-blind radiostereometric study of 50 patients. Acta Orthopaedica 2007;78:795-9.
12. Friedl G, Radl R, Stihsen C, et al. The Effect of a Single Infusion of Zoledronic Acid on Early Implant Migration in Total Hip Arthroplasty. A Randomized, Double-Blind, Controlled Trial. J Bone Joint Surg Am 2009;91:274-81.
13. Hansson U, Toksvig-Larsen S, Ryd L, et al. Once-weekly oral medication with alendronate does not prevent migration of knee prostheses. Acta Orthopaedica 2009;80:41-5.
14. Walley T, Mantgani A. The UK General Practice Research Database. The Lancet 1997;350:1097-9.
15. Prieto-Alhambra D, Javaid MK, Judge A, et al. Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study. BMJ 2011;343:d7222.
16. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
17. Tannen RL, Weiner MG, Xie D. Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. BMJ 2009;338.
18. Royston P. Multiple imputation of missing values: Update of ice. Stata Journal 2005;5:527-36.
19. Austin PC. Some Methods of Propensity-Score Matching had Superior Performance to Others: Results of an Empirical Investigation and Monte Carlo simulations. Biom J 2009;51:171-84.
20. Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006;98:253-9.
21. Zhou Z, Rahme E, Abrahamowicz M, et al. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol 2005;162:1016-23.
22. diPrete TA, Gangl M. Assessing Bias in the Estimation of Causal Effects: Rosenbaum Bounds on Matching Estimators and Instrumental Variables Estimation with Imperfect Instruments. Sociological Methodol 2004;34:271-310.
23. Rosenbaum PR, Rubin DB. Assessing Sensitivity to an Unobserved Binary Covariate in an Observational Study with Binary Outcome. J Royal Stat Soc, Series B (Methodol) 1983;45:212-18.
24. Abu-Amer Y, Darwech I, Clohisy J. Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies. Arthritis Res Ther 2007; 9(Suppl 1):S6.
25. Zeng Y, Lai O, Shen B, et al. A systematic review assessing the effectiveness of alendronate in reducing periprosthetic bone loss after cementless primary THA. Orthopedics 2011;34.
26. Giro G, Coelho PG, Pereira RM, et al. The effect of oestrogen and alendronate therapies on postmenopausal bone loss around osseointegrated titanium implants. Clin Oral Implants Res 2010;22:259-64.
27. Shih LY, Shih HN, Chen TH. The effects of sex and estrogen therapy on bone ingrowth into porous coated implant. J Orthop Res 2003;21:1033-40.
28. Giro G, Goncalves D, Sakakura CE, et al. Influence of estrogen deficiency and its treatment with alendronate and estrogen on bone density around osseointegrated implants: radiographic study in female rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:162-7.
29. Nociti FH Jr., Sallum AW, Sallum EA, et al. Effect of estrogen replacement and calcitonin therapies on bone around titanium implants placed in ovariectomized rats: a histometric study. Int J Oral Maxillofac Implants 2002;17:786-92.
30. Qi MC, Zhou XQ, Hu J, et al. Oestrogen replacement therapy promotes bone healing around dental implants in osteoporotic rats. Int J Oral Maxillofac Surg 2004;33:279-85.
31. August M, Chung K, Chang Y, et al. Influence of estrogen status on endosseous implant osseointegration. J Oral Maxillofac Surg 2001;59:1285-9; discussion 1290-1281.
32. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684-92.
33. Harman SM, Vittinghoff E, Brinton EA, et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med 2011;124:199-205.
34. Canonico M, Plu-Bureau G, Lowe GD, et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336:1227-31.
35. Normand S-LT, Sykora K, Li P, et al. Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. BMJ 2005;330:1021-3.
36. National Joint Registry. National Joint Registry for England and Wales. 9th Annual Report; 2012.